How a company communicates with investors can be just as meaningful as what it communicates.
Take Applied Therapeutics, which used an SEC filing on Monday morning to disclose that the Food and Drug Administration placed a partial hold on one of its important clinical trials, involving its lead drug and children with a rare metabolic disease.
Applied Therapeutics did not issue an accompanying press release, nor did CEO Shoshana Shendelman convene a conference call to update shareholders, even though the development of its lead drug, called AT-007, is now delayed.
About the Author Reprints
